Novo Nordisk Weight Loss Pill Tops 3 Million Prescriptions
Novo Nordisk’s oral weight-loss pill has reached three million prescriptions in the United States since its launch, marking a major early milestone for the drugmaker’s effort to expand access beyond injectable treatments.
The figure covers U.S. prescriptions written since the pill became available in January, according to recent reports citing Novo Nordisk’s prescription data. The product is tied to the company’s Wegovy franchise, a leading brand in the fast-growing market for obesity medicines.
Novo Nordisk, headquartered in Denmark, has built its weight-loss business around GLP-1 drugs that help patients reduce weight. The company’s injectable Wegovy has been one of the most visible products in the category. The prescription milestone highlights the company’s progress in bringing a pill option to patients and clinicians who prefer an oral medication.
The U.S. market is the biggest battleground for weight-loss drugs, and prescription volume is a key measure of adoption. Hitting three million prescriptions within months underscores how quickly an oral option can scale once it reaches pharmacies and physician offices.
This development matters because oral dosing can change how widely obesity treatment is used. Many patients are more comfortable starting a daily pill than taking a weekly injection, and doctors may find it easier to discuss and prescribe an oral medication during routine visits. A pill can also simplify distribution and administration, potentially broadening the pool of patients who consider treatment.
The milestone also lands as competition intensifies between Novo Nordisk and Eli Lilly, the other major player in the category. Investors have been closely tracking updates from both companies, including prescription totals, clinical results, and other signs of momentum as the market grows.
For Novo Nordisk, the rapid prescription count is another data point that the demand for weight-loss medications remains strong. It also signals that the company’s strategy to offer more than one format—shots and pills—can help it defend and expand its position.
What happens next will depend on how prescription trends hold, and on how broadly clinicians continue to adopt the pill alongside injectable therapies. The market is also watching for additional updates from competitors and for any new developments that could influence prescribing, including clinical announcements and company guidance.
Novo Nordisk’s three-million-prescription mark sets a high bar for early uptake and adds fresh pressure to a crowded field racing to meet demand for modern weight-loss treatment.
